The global human papillomavirus testing market size was estimated to be US$ 850 million in 2021 and is expected grow at a CAGR of 12.5% between 2023 to 2032.
Human Papilloma Viruses are a group of more than 150 related viruses which generally infect the squamous epithelial cells in humans. They can only survive in these cell types and cause skin diseases like warts and noncancerous tumours. However, some types of HPV can cause cancer in the cervix, vulva, anus, and penis by infecting the mucosal surfaces. The earlier types of HPV are not considered lethal whereas the latter are major agents of cervical cancers.
Early diagnosis of abnormal or virus-infected cells can greatly affect cancer progression and treatment. The most commonly used tests for the diagnosis of cervical cancer are the HPV and Pap tests. The Pap test is a smear test used to measure abnormal cervical cells, whereas the HPV test can help in the detection of HPV in the cervix which can cause cancer.
Usually, a person having abnormal cells in the Pap test is suggested to undergo HPV testing. This group is considered high-risk and is the biggest contributor to the global HPV testing market. The low-risk group consists of individuals with cervical infections, and people having recurrent or persistent HPV infections in other parts. These groups of individuals hold a small share in the use of HPV testing services. Because there is a rising need for innovation and alternative methods in cancer diagnostics and to detect of human papillomavirus (HPV) associated cancer growth in Global Human Papillomavirus Testing Market is expected within the next decade.
Factors contributing to growth of HPV testing:
Increasing awareness of the link between cervical cancer and HPV infection has caused a big increase in demand for these tests in clinical and diagnostic settings. The global human papillomavirus testing market may experience growth due to an increase in the prevalence of cervical cancer and a subsequent rise in high-risk patients.
The rising female geriatric population may also help in the rising demand for human papillomavirus testing services globally. Increased risk due to comorbidities and co-infection has already propelled the global testing market and will continue to help increase the demand for HPV testing as well. Rising mortality in patients affected with cervical cancer is also anticipated to boost the growth of the HPV testing market within the forecast period.
New technologies like automated testing protocols, faster and reliable results, reduction in cost due to the scale of the economy, and a rise in cancer patient care will also contribute to the cervical cancer diagnostics and global human papillomavirus testing market.
Primary screening tests for cancer-associated factors are less sensitive to HPV and can cause false negatives. This coupled with better accuracy of direct human papillomavirus testing has increased the desirability of these services. Moreover, the HPV-induced cervical cancer risk for females vaccinated with HPV vaccines largely remains unchanged. Therefore, the demand for human papillomavirus testing in vaccinated females also spurs the growth of this testing.
Growth opportunities for molecular diagnostic in HPV testing:
Molecular diagnostics of HPV is the primary driver of the human papillomavirus testing market across the globe. Simple and precise detection of several types of HPV, and the inability of culturing methods to grow HPV in the lab have significantly increased the use of molecular methods for HPV testing.
Molecular methods also provide tools like target amplification, and probe amplification which can result in the enhancement of signals and better detection even if the infection is in nascent stages. All these existing benefits of molecular diagnostic methods for HPV will lead the growth trajectory of the HPV testing market across the world.
Advancement of screening technologies and increased specificity has enabled rapid detection of disease markers as required instead of relying on predisposing factors. This will also help the adoption of human papillomavirus testing services throughout all the regions.
Furthermore, the lack of resources and economic constraints cause significant hurdles in the progress of cytology-based diagnostic screening. This is because cytology detection requires higher input costs, better infrastructure, thoroughly trained professionals, and quality control regimens. This paired with the lower sensitivity of conventional cytological screening has greatly favoured the implementation of direct HPV testing services.
Therefore, HPV testing procedures have evolved as a consequence of the failure of cytology-based testing and low-resource demand and have greatly capitulated the growth of the global human papillomavirus testing market, especially across poor and developing economies.
Regional Trends of the Global HPV Diagnostic Market
The HPV diagnostic market is largely based in the North America region. Increased awareness of diagnostic techniques has resulted in a demand for early diagnosis, especially in the USA and Canada. The rising incidence of cervical cancer among the female population and the growing preference of clinicians has also spurred the growth of human papillomavirus testing in the North American markets.
Apart from North America, the Asia-Pacific region is also expected to experience substantial growth in the HPV testing market. Here as well the increased prevalence of cervical cancer and HPV infection will be primary drivers of the HPV testing demand. The presence of a large population and higher incidence of other sexually transmitted diseases will enable the growth of the human papillomavirus testing market in this region.
Prominent players like Abbott Labs., Biomedical Diagnostics Inc., bioMerieux, Bio-Rad, Epigenomics, Gen-Probe, OncoLab, Radient Pharmaceuticals, Roche, Sequenom, Siemens Healthcare, and Qiagen, have a major presence in the global HPV testing market.
Competitive market strategies are being employed by these companies to ensure growth and sales which will positively help the HPV testing market at large. Compliance with new guidelines and better development strategies have also helped achieve quick product approvals and enhanced individual market positions.
Global HPV Diagnostic Market Segmentation:
By Product types
- Consumables
- Types of equipment
By End User
- Diagnostic Centers
- Hospitals
- Clinics
By Geography
- North America
- United States
- Canada
- Rest of North America
- Europe
- Germany
- United Kingdom
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- India
- China
- Australia
- Rest of Asia Pacific
- Middle East & Africa
- UAE
- Saudi Arabia
- South Africa
- Rest of the Middle East & Africa
- South America
- Brazil
- Rest of South America
